MedTrace Logo

Plasmodium Immunotherapy for Lung Cancer

NCT02786589 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-06-22

No results posted yet for this study

Summary

The objective of this study is to evaluate the safety and the effectiveness of Plasmodium immunotherapy (blood-stage infection of Plasmodium vivax) for advanced non-small cell lung cancer.The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.

Conditions

  • Lung Cancer, Nonsmall Cell

Interventions

BIOLOGICAL

Blood-stage infection of P. vivax

Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1×10\^7 Plasmodium parasites.And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples.The treatment will last at least 12 weeks from the day of finding the Plasmodium from peripheral blood and will be terminated by chloroquine phosphate or Artemisinin compound preparation or Artesunate injection.

Sponsors & Collaborators

  • CAS Lamvac Biotech Co., Ltd.

    collaborator INDUSTRY

  • State Key Laboratory of Respiratory Disease

    lead OTHER

Principal Investigators

  • Ming Ou-Yang, M.D. · The First Affiliated Hospital, Guangzhou Medical University，China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-27
Primary Completion
2020-07-01
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02786589 on ClinicalTrials.gov